Neuronetics Inc (STIM) - Total Assets
Based on the latest financial reports, Neuronetics Inc (STIM) holds total assets worth $125.44 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check STIM total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Neuronetics Inc - Total Assets Trend (2016–2025)
This chart illustrates how Neuronetics Inc's total assets have evolved over time, based on quarterly financial data. Explore STIM long-term investment intensity to see how much of total assets are deployed in long-term investments.
Neuronetics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Neuronetics Inc's total assets of $125.44 Million consist of 43.5% current assets and 56.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.1% |
| Accounts Receivable | $16.89 Million | 11.9% |
| Inventory | $4.33 Million | 3.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $18.15 Million | 12.8% |
| Goodwill | $23.62 Million | 16.7% |
Asset Composition Trend (2016–2025)
This chart illustrates how Neuronetics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see STIM company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuronetics Inc's current assets represent 43.5% of total assets in 2025, a decrease from 92.4% in 2016.
- Cash Position: Cash and equivalents constituted 24.1% of total assets in 2025, down from 68.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 28.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 16.7% of total assets.
Neuronetics Inc Competitors by Total Assets
Key competitors of Neuronetics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Neuronetics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.67 | 2.44 | 11.65 |
| Quick Ratio | 1.50 | 2.28 | 11.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $18.89 Million | $35.83 Million | $123.30 Million |
Neuronetics Inc - Advanced Valuation Insights
This section examines the relationship between Neuronetics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.51 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | 0.5% |
| Total Assets | $141.55 Million |
| Market Capitalization | $84.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values Neuronetics Inc's assets below their book value (0.59x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Neuronetics Inc's assets grew by 0.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Neuronetics Inc (2016–2025)
The table below shows the annual total assets of Neuronetics Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $141.55 Million | +0.46% |
| 2024-12-31 | $140.90 Million | +21.65% |
| 2023-12-31 | $115.83 Million | -0.90% |
| 2022-12-31 | $116.88 Million | -17.23% |
| 2021-12-31 | $141.22 Million | +79.54% |
| 2020-12-31 | $78.66 Million | -21.47% |
| 2019-12-31 | $100.17 Million | -14.40% |
| 2018-12-31 | $117.02 Million | +200.53% |
| 2017-12-31 | $38.94 Million | +57.02% |
| 2016-12-31 | $24.80 Million | -- |
About Neuronetics Inc
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a p… Read more